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Abstract
Background: The lipogenic enzyme fatty acid synthase (FAS) is up-regulated in a wide variety of
cancers, and is considered a potential metabolic oncogene by virtue of its ability to enhance tumor
cell survival. Inhibition of tumor FAS causes both cell cycle arrest and apoptosis, indicating FAS is
a promising target for cancer treatment.
Results:  Here, we used gene expression profiling to conduct a global study of the cellular
processes affected by siRNA mediated knockdown of FAS in MDA-MB-435 mammary carcinoma
cells. The study identified 169 up-regulated genes (≥ 1.5 fold) and 110 down-regulated genes (≤ 0.67
fold) in response to knockdown of FAS. These genes regulate several aspects of tumor function,
including metabolism, cell survival/proliferation, DNA replication/transcription, and protein
degradation. Quantitative pathway analysis using Gene Set Enrichment Analysis software further
revealed that the most pronounced effect of FAS knockdown was down-regulation in pathways that
regulate lipid metabolism, glycolysis, the TCA cycle and oxidative phosphorylation. These changes
were coupled with up-regulation in genes involved in cell cycle arrest and death receptor mediated
apoptotic pathways.
Conclusion: Together these findings reveal a wide network of pathways that are influenced in
response to FAS knockdown and provide new insight into the role of this enzyme in tumor cell
survival and proliferation.
Background
Up-regulation of fatty acid synthase (FAS), the enzyme
responsible for the endogenous synthesis of palmitate, is
increasingly recognized as a hallmark of cancer [1,2].
While normal cells obtain most fatty acids from circulat-
ing lipids, tumor cells have developed an increased reli-
ance on endogenous fatty acid synthesis to satisfy their
metabolic needs [2]. This elevation of FAS occurs early in
human cancer, is associated with aggressive forms of the
disease, and is linked to poor prognosis [3-7]. Conse-
quently, strategies to target FAS are becoming increasingly
exploited as attractive approaches for cancer therapy.
FAS is critically important for tumor cell survival and
function; providing the necessary fatty acids for mem-
brane formation and signal transduction [2]. The targeted
knockdown of tumor FAS by small molecule inhibitors or
small interfering RNA (siRNA) has been shown to induce
both cell cycle arrest and apoptosis in cultured cells and
suppresses tumor growth in xenograft bearing mice [8-
13]. This anti-tumor activity is linked to increased expres-
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sion of p27kip1 [9,14] and decreased Akt phosphorylation
[15]. FAS inhibition can also lead to the transcriptional
suppression of the Her2/neu gene suggesting an active role
for FAS in gene regulation [16]. However, detailed under-
standing of the regulatory mechanisms linking inhibition
of FAS to these anti-tumor effects remains elusive.
In the present study, we utilized siRNA, BeadArray tech-
nology, and pathway analysis to define the genome-wide
changes that take place following knockdown of FAS (12–
48 h). We have identified a core set of 279 genes repre-
senting the FAS knockdown signature in the MDA-MB-
435 mammary carcinoma cell model. Functional classifi-
cation of these target genes, combined with quantitative
pathway analysis, revealed extensive changes in metabo-
lism, cell survival/proliferation, DNA replication/tran-
scription, and ubiquitin dependent protein degradation
as a consequence of FAS inhibition. Taken together, our
results provide a detailed overview of the anti-tumori-
genic signaling network induced in tumor cells by the tar-
geted knockdown of FAS.
Results
Changes in gene expression resulting from knockdown of 
FAS
MDA-MB-435 mammary carcinoma cells were selected as
the model for defining the FAS knockdown signature. For
our experiment, four independent siRNA duplexes target-
ing FAS (FAS #1-#4) were chosen based on there ability to
knockdown the enzyme and to induce tumor cell apopto-
sis after 72 h [17]. Inhibition of FAS by each duplex was
verified using 25 nM of siRNA as demonstrated by a
decrease in FAS mRNA, protein, and fatty acid biosynthe-
sis after 48 h relative to non-silencing control siRNA (Fig-
ure 1a–c). The non-silencing control siRNA was selected
based on minimal cross reactivity with known targets and
had no impact on FAS expression or activity when com-
pared against Lipofectamine 2000 transfection alone
(data not shown). Gene expression profiles were exam-
ined on two separate occasions following transfection
with FAS siRNA. Treatment times (12, 24, 36 and 48 h)
were chosen to capture early and late gene changes associ-
ated with the block in cell cycle progression and the
advent of apoptosis occurring in response to knockdown
of FAS. Abrogation of FAS (>70%) was verified within 12
h of transfection and persisted throughout the 48 h exper-
iment. Significant changes in cell viability were not
observed 48 h post-transfection indicating cells were via-
ble during the time of gene analysis (data not shown).
The first approach we used in analyzing the effect of
knockdown of FAS on gene expression was to identify tar-
get genes modified by at least 3 of the siRNA duplexes. The
expression signature of each FAS siRNA was determined
by identifying genes significantly changed over the time
course using MB statistics and two way ANOVA analysis.
For each siRNA duplex only genes with a p-value ≤ 0.05
and at least 1.2 fold changes in both biological replicates
at a given time point were maintained for expression anal-
ysis, and are published as supporting information online
(see Additional Files 1, 2, 3, and 4). The FAS knockdown
signature was defined as the overlap of significant gene
changes occurring in response to at least 3 of the siRNA
duplexes with an average gene expression change 1.5 fold
that observed in controls. This allowed us to identify gene
changes specifically associated with knockdown of FAS,
while at the same time eliminate potential off-target
effects unique to the individual siRNA sequences. Using
this approach, we identified 279 genes whose expression
changed in response to knockdown of FAS (169 genes up-
regulated and 110 down-regulated; see Additional File 5).
Alterations in gene expression occurred as early as 12 h
after knockdown of FAS with the majority of genes
affected by 24 h (Figure 1d). These results show that inac-
tivation of FAS has a profound affect on gene transcrip-
tion.
Knockdown of FAS affected genes that regulate a variety of
biological processes including cell proliferation, DNA rep-
lication, transcription and apoptosis (Table 1; see Addi-
tional File 5). We found that the abrogation of FAS
enhanced the expression of several anti-proliferative genes
including CCNG1, CDKN1A (p21cip1), SPRY2 and
SPRY4. This coincided with up-regulation of the cell sur-
face apoptosis gene ANXA1, the mitochondrial apoptosis
pathway gene APAF1, and the death receptors TNFRSF10B
(TNF-related apoptosis-inducing ligand (TRAIL) receptor)
and TNFRSF21 (TNF-α receptor). In addition, results
showed knockdown of FAS up-regulates SGPL1, a key
enzyme in sphingosine-1-phosphate metabolism whose
increased expression also leads to accumulation of the
pro-apoptotic signaling molecule ceramide [18]. This
finding is consistent with reports that FAS inhibition up-
regulates ceramide synthesis, which has been found to be
a necessary step leading to the induction of tumor cell
apoptosis following the loss of FAS [17].
Several of the genes significantly altered by knockdown of
FAS are known to play a role in the regulation of lipid
metabolism. Inactivation of FAS increased the expression
of INSIG1, and the leptin receptors, LEPR and LEPROTL1,
which block transcription, proteolytic cleavage and tran-
scriptional activation of the sterol regulatory element-
binding protein (SREBP) family of transcription factors
that promote lipid biosynthesis (Table 1) [19,20]. Addi-
tionally, loss of FAS led to down-regulation of ID2 and
ID3, which are dominant negative helix-loop-helix (HLH)
proteins that bind SREBP 1c and functionally repress FAS
promoter activity [21]. ID2 and ID3 also repress expres-
sion of the cyclin-dependent kinase inhibitor p21cip1BMC Genomics 2007, 8:168 http://www.biomedcentral.com/1471-2164/8/168
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FAS knockdown generates specific and time-dependent gene expression patterns Figure 1
FAS knockdown generates specific and time-dependent gene expression patterns. (a-c) Target mRNA, protein 
and fatty acid biosynthesis knockdown by FAS siRNA duplexes. MDA-MB-435 tumor cells were exposed to 25 nM of four dif-
ferent siRNA duplexes targeted against FAS (FAS #1-#4) or non-silencing control siRNA for 48 h. Efficiency of FAS knockdown 
was determined by measuring FAS mRNA (a), FAS protein (b) and fatty acid biosynthesis (c). β-tubulin served as a loading con-
trol for FAS protein expression. Values are the mean ± SE of two replicates per treatment. (d) Expression profile represents 
279 genes differentially modified by 1.5 fold in response to knockdown of FAS (shown in hours on the X-axis). Horizontal lines 
represent the average expression of individual genes modified by at least 3 of the FAS siRNA duplexes. Red and green indicate 
increased and decreased expression, respectively, relative to non-silencing control siRNA.
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Table 1: Selected FAS target genes involved in proliferation/apoptosis, metabolism, transcription and protein ubiquitination.
Gene Classication/Description Symbol 12 h Fold Δ 24 h Fold Δ 36 h Fold Δ 48 h Fold Δ Gene Identifier
Proliferation
Up-regulated
Cell division cycle associated 4 CDCA4 1.43 1.63 1.82 1.59 GI_22027510-A
Cyclin G1 CCNG1 0.94 1.55 1.41 1.37 GI_40805830-S
Cyclin-dependent kinase 2 CDK2 1.14 1.60 1.43 1.39 GI_16936529-A
Cyclin-dependent kinase inhibitor 1A (p21, Cip1) CDKN1A 1.60 1.60 1.84 1.82 GI_17978496-A
Polo-like kinase 1 PLK1 1.24 1.35 1.48 1.59 GI_34147632-S
Sprouty homolog 2 SPRY2 1.39 1.68 1.60 1.58 GI_22209007-S
Sprouty homolog 4 SPRY4 1.08 1.43 1.45 1.56 GI_23308573-S
Sprouty-related, EVH1 domain containing 1 SPRED1 1.18 1.36 1.59 1.47 GI_22749220-S
WEE1 homolog WEE1 1.37 1.55 1.65 1.67 GI_19718775-S
Apoptosis
Up-regulated
Annexin A1 ANXA1 1.29 1.93 1.90 1.63 GI_4502100-S
Apoptotic protease activating factor APAF1 1.28 1.72 1.48 1.39 GI_32483362-A
CSE1 chromosome segregation 1-like CSE1L 1.05 1.46 2.40 2.07 GI_29029560-I
P21 (CDKN1A)-activated kinase 2 PAK2 1.13 1.44 1.46 1.71 GI_32483398-S
Sphingosine-1-phosphate lyase 1 SGPL1 1.42 1.55 1.67 1.72 GI_31982935-S
Tumor necrosis factor receptor superfamily, member 10b TNFRSF10B 1.32 1.81 1.76 1.49 GI_22547118-A
Tumor necrosis factor receptor superfamily, member 21 TNFRSF21 1.20 1.71 1.88 1.73 GI_23238206-S
Metabolism
Up-regulated
Insulin induced gene 1 INSIG1 1.51 1.51 1.56 1.51 GI_38327530-A
Leptin receptor LEPR 1.30 1.60 1.63 1.59 GI_41327153-S
Leptin receptor overlapping transcript-like 1 LEPROTL1 1.11 1.62 1.59 1.45 GI_7662509-S
Transcription
Up-regulated
E2F transcription factor 7 E2F7 1.26 1.32 1.50 1.47 GI_44955909-S
Early growth response 1 EGR1 1.56 1.56 1.84 1.82 GI_31317226-S
Far upstream element (FUSE) binding protein 1 FUBP1 1.15 1.12 1.51 1.52 GI_17402899-S
FBJ murine osteosarcoma viral oncogene homolog B FOSB 1.44 1.40 1.66 1.78 GI_5803016-S
FOS-like antigen 1 FOSL1 1.11 1.44 1.65 1.59 GI_34734076-S
Kruppel-like factor 4 (gut) KLF4 1.04 1.47 1.61 1.36 GI_34916057-S
Meis1, myeloid ecotropic viral integration site 1 homolog MEIS1 1.12 1.50 1.33 1.30 GI_45006902-S
Nuclear factor I/A NFIA 1.13 1.40 1.41 1.52 GI_30840979-S
Nuclear factor I/B NFIB 2.10 2.24 2.29 2.16 GI_5031940-S
Nuclear factor of activated T-cells, cytoplasmic, calcineurin-
dependent 3
NFATC3 1.31 1.52 1.48 1.50 GI_27886558-A
Paired related homeobox 1 PRRX1 0.96 1.35 1.59 1.59 GI_12707576-A
Protein phosphatase 1, regulatory (inhibitor) ELF2 1.30 1.34 1.54 1.41 GI_42544175-A
Serum response factor SRF 1.55 1.44 1.35 1.26 GI_4507204-SBMC Genomics 2007, 8:168 http://www.biomedcentral.com/1471-2164/8/168
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SP110 nuclear body protein SP110 1.02 1.25 1.33 1.63 GI_17986251-I
Zinc finger protein 106 homolog ZFP106 1.33 1.58 1.66 1.68 GI_11968022-S
Zinc finger protein 267 ZNF267 1.25 1.53 1.75 1.52 GI_24431954-S
Zinc finger protein 35 (clone HF.10) ZNF35 1.55 1.70 1.60 1.58 GI_21361560-S
Zinc finger protein 426 ZNF426 1.36 1.52 1.37 1.35 GI_13129115-S
Zinc finger protein 503 ZNF503 1.28 1.53 1.37 1.28 GI_34222201-S
Zinc finger protein 539 ZNF539 1.04 1.50 1.29 1.13 GI_4758513-S
Zinc finger protein 559 ZNF559 1.48 1.76 1.59 1.53 GI_23618925-S
Zinc finger protein 586 ZNF586 1.73 1.63 1.63 1.51 GI_8923076-S
Zinc finger protein 91 homolog ZFP91 1.13 1.42 1.60 1.26 GI_25777699-I
Down-regulated
Aryl-hydrocarbon receptor nuclear translocator 2 ARNT2 0.85 0.79 0.62 0.76 GI_41281514-S
CAMP responsive element binding protein 3-like 4 CREB3L4 0.92 0.66 0.66 0.76 GI_31542090-S
Hypothetical protein FLJ37970 FLJ37970 1.08 0.79 0.81 0.67 GI_40795670-S
Inhibitor of DNA binding 2, dominant negative helix-loop-helix 
protein
ID2 1.00 0.79 0.61 0.71 GI_33946335-S
Inhibitor of DNA binding 3, dominant negative helix-loop-helix 
protein
ID3 0.93 0.69 0.57 0.56 GI_32171181-S
Neuronal PAS domain protein 1 NPAS1 0.90 0.82 0.71 0.64 GI_22027481-S
Oligodendrocyte transcription factor 1 OLIG1 0.78 0.83 0.69 0.68 GI_41281694-S
Signal transducer and activator of transcription 2, 113 kDa STAT2 0.90 0.86 0.64 0.71 GI_38202247-S
Ubiquitination
Up-regulated
Ubiquitin-conjugating enzyme E2 variant 1 UBE2V1 1.79 2.54 2.45 2.11 GI_40806192-S
Ubiquitin-conjugating enzyme E2 variant 1 UBE2V1 1.65 1.73 1.83 1.67 GI_40806191-I
Ubiquitin-conjugating enzyme E2E 3 (UBC4/5 homolog) UBE2E3 1.62 2.21 2.27 2.14 GI_33359693-A
Ubiquitin-conjugating enzyme E2C UBE2C 1.09 1.11 1.52 1.25 GI_32967282-I
CDC23 (cell division cycle 23, yeast, homolog) CDC23 1.24 1.75 1.67 1.60 GI_16554575-S
Ring finger protein 144 RNF144 1.52 1.52 1.47 1.51 GI_38045937-S
Makorin, ring finger protein, 1 MKRN1 1.41 1.75 1.64 1.49 GI_21359891-S
F-box and leucine-rich repeat protein 12 FBXL12 1.56 1.81 1.55 1.61 GI_8923178-S
F-box and leucine-rich repeat protein 7 FBXL7 1.52 1.62 1.64 1.68 GI_21071079-S
Ubiquitin-like, containing PHD and RING finger domains, 1 UHRF1 1.15 1.55 1.36 1.35 GI_16507203-S
APG12 autophagy 12-like APG12L 1.32 1.27 1.54 1.24 GI_38261968-S
Down-regulated
Membrane-associated ring finger (C3HC4) 2 MARCH-II 0.99 0.72 0.60 0.59 GI_31543081-S
SH3 domain containing ring finger 2 SH3RF2 1.00 0.89 0.84 0.66 GI_22749146-S
Tripartite motif-containing 2 TRIM2 0.78 0.83 0.60 0.76 GI_15011942-S
Tripartite motif-containing 37 TRIM37 0.75 0.64 0.64 0.70 GI_15147332-S
The fold change values represent the average from at least 3 of the FAS siRNA duplexes compared to non-silencing control siRNA. Genes were classified using GO 
terminology from GeneSpring and the NCBI Nucleotide database. For detailed annotations of all 279 differentially expressed genes see Additional File 5.
Table 1: Selected FAS target genes involved in proliferation/apoptosis, metabolism, transcription and protein ubiquitination. (Continued)BMC Genomics 2007, 8:168 http://www.biomedcentral.com/1471-2164/8/168
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[22,23], thus, as expected the suppression of these genes
in response to knockdown of FAS was coupled with up-
regulation of the p21cip1 gene (Table 1). These data provide
evidence of a direct link between regulation of FAS and
control of cell cycle progression.
Another important biological category affected by knock-
down of FAS is regulation of protein ubiquitination
(Table 1). We found that knockdown of FAS altered the
expression of several E2 ubiquitin conjugation enzymes
(2 up-regulated) and E3 ubiquitin ligases (4 down-regu-
lated and 6 up-regulated) which function to target pro-
teins for degradation by the proteosome [24]. In addition,
we identified up-regulation of 2 splice variants of
UBE2V1, which are catalytically inactive E2 enzymes [25].
UBE2V1 variants result from the co-transcription of
UBE2V1 with the neighboring upstream gene, Kua, which
shares sequence consensus to fatty acid hydrolases (vari-
ant 2, Kua-UEV fusion gene [GI_40806191-I]; variant 4,
Kua gene [GI_40806192-I]). This targeting of ubiquitina-
tion enzymes indicates that the knockdown of FAS affects
the tumor cell proteome not only through changes in
transcription, but also on the post-translational level.
Knockdown of FAS leads to widespread changes in 
pathways involved in metabolism
The second approach we used to analyze the gene array
results was to identify gene pathways coordinately up-reg-
ulated or down-regulated by knockdown of FAS using
Gene Set Enrichment Analysis (GSEA). GSEA is a unique
application that coordinates small changes in gene expres-
sion from a large number of functionally related genes in
order to identify pathways that are significantly changed
[26]. As expected, fatty acid metabolism (NES = -1.808,
NOM p-val = 0.002, FDR q-val = 0.085) was significantly
suppressed by knockdown of FAS (Figure 2). Fatty acid
elongation (NES = -1.537, NOM p-val = 0.037, FDR q-val
= 0.394) was also reduced, which is consistent with the
loss of available palmitate.
The effects of knockdown of FAS on the expression of met-
abolic genes extended to pathways other than fatty acid
metabolism (Figure 2). Inactivation of FAS down-regu-
lated both the glycolysis/gluconeogenesis (NES = -1.560,
NOM p-val = 0.029, FDR q-val = 0.377) and krebs-TCA
cycle (NES = -1.737, NOM p-val = 0.014, FDR q-val =
0.094) pathways. Down-regulation of the krebs-TCA cycle
was consistent with an overall suppression in mitochon-
drial genes involved in energy metabolism and oxidative
phosphorylation (GO 005739; NES = -1.515, NOM p-val
= 0.039, FDR q-val = 0.365). Furthermore, this down-reg-
ulation in genes regulating glucose utilization was cou-
pled with a reduction in insulin signaling (NES = -1.635,
NOM p-val = 0.005, FDR q-val = 0.280). This suggests that
inhibition of FAS may restrict the ability of tumor cells to
produce the energy necessary to thrive.
Knockdown of FAS up-regulates pathways involved in cell 
cycle arrest and apoptosis
The anti-tumorigenic effects of knockdown of FAS were
traced to an up-regulation in genes that modify tumor
proliferation (Figure 3). GSEA analysis showed that
knockdown of FAS up-regulated genes involved in DNA
damage signaling (NES = 1.809, NOM p-val = 0.000, FDR
q-val = 0.068) and cell cycle arrest (NES = 1.504, NOM p-
val = 0.036, FDR q-val = 0.163). Induction of cell cycle
arrest was coupled with up-regulation of the p27 (NES =
1.582, NOM p-val = 0.009, FDR q-val = 0.128) and Rb
(NES = 1.581, NOM p-val = 0.010, FDR q-val = 0.126)
pathways consistent with our previous finding that FAS
regulates the G1 checkpoint through these pathways [9].
Additionally, knockdown of FAS elevated the expression
of several cyclin-dependent kinase inhibitors (p16INK4
(CDKN2A),  p15INK4  (CDKN2B) and p21Cip1) which
function as negative regulators of the Rb pathway [27],
demonstrating FAS induces a high degree of regulation
over the G1/S transition (Figure 3). Results also showed
that knockdown of FAS elevated genes involved in the G2
pathway including the checkpoint regulators CHEK2,
WEE1 and PLK1 (Table 1; Figure 3). These data indicate
that FAS controls tumor proliferation by regulating several
aspects of the cell division cycle.
The apoptotic effects of knockdown of FAS were recently
shown to be blocked by co-treatment with the pan-cas-
pase inhibitor z-VAD-fmk [28], suggesting a role for cas-
pases in mediating FAS induced tumor cell death. Here,
we found up-regulation of caspase 7 and caspase 8 (recep-
tor-mediated apoptosis) in response to knockdown of
FAS (Figure 3). This was accompanied by enhanced
expression of pathways and genes that activate caspase 8
such as tumor necrosis factor (tnfr1, NES = 1.408, NOM
p-val = 0.038, FDR q-val = 0.230; tnfr2, NES = 1.788,
NOM p-val = 0.002, FDR q-val = 0.070; Figure 3). GSEA
results also demonstrated compensatory up-regulation of
NF-κB (NF-κB Induced, NES = 1.5, NOM p-val = 0.022,
FDR q-val = 0.166) and the MAP kinase (NES = 1.539,
NOM p-val = 0.016, FDR q-val = 0.133) survival pathways
in line with previous reports (see Additional File 7; [14]).
Discussion
The present study provides a comprehensive overview of
the genomic changes accompanying knockdown of tumor
FAS. To our knowledge, this is the first report demonstrat-
ing that targeted knockdown of a metabolic enzyme can
influence overall energy producing pathways within the
tumor cell. The major findings of this work are as follows:
first, siRNA mediated knockdown of FAS affects the tran-
scription of genes involved in tumor cell energy metabo-BMC Genomics 2007, 8:168 http://www.biomedcentral.com/1471-2164/8/168
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Down-regulation of metabolic pathways by targeted knockdown of FAS Figure 2
Down-regulation of metabolic pathways by targeted knockdown of FAS. The figure displays select pathways found 
to be down-regulated in response to FAS siRNA treatment compared to non-silencing control siRNA. Significance was deter-
mined using a nominal p-value < 0.05 or FDR < 0.250. The expression levels of the genes significantly modified in the pathway 
are coded colorimetrically: red, high expression; blue, low expression. FAS siRNA treatments for each time point are ordered 
as follows (a and b indicate different biological replicates): FAS #1a, FAS #1b, FAS #2a, FAS #2b, FAS #3a, FAS #3b, FAS #4a, 
FAS #4b. For a complete list of all pathways down-regulated by knockdown of FAS, see Additional File 6.
Gene Symbol Gene ID FAS knockdown signature Gene Symbol Gene ID FAS knockdown signature
fatty_acid_metabolism MAP00062_Fatty_acid_biosynthesis_path_2 (Elongation)
FASN GI_41872630-S ACAA1 GI_6598316-S
ACADSB GI_38373685-S HADHB GI_4504326-S
DHRS3 GI_34222303-S ACAT1 GI_31563501-S
ASAH1 GI_30089927-A EHHADH GI_4503496-S
PCCA GI_4557832-S ACAA2 GI_5174428-S
PECR GI_19923816-S ECHS1 GI_12707569-S
CYP2J2 GI_18491007-S
FABP7 GI_36054052-S GO_0005739 (Mitochondria)
PECI GI_45643118-A ACADSB GI_38373685-S
ACP6 GI_21359910-S
Krebs-TCA_Cycle PCCB GI_24475879-S
DLAT GI_31711991-S PCK2 GI_4758885-S
MDH1 GI_21735619-S FDXR GI_13435349-A
DLD GI_5016092-S DLAT GI_31711991-S
OGDH GI_4505492-S BDH GI_44680134-A
PDHA1 GI_4505684-S CKMT1 GI_11641403-S
PDK3 GI_4885544-S CYCS GI_34328939-S
SDHA GI_4759079-S DLD GI_5016092-S
IDH3A GI_28178835-S DNASE2 GI_4503348-S
PDHB GI_4505686-S SLC25A4 GI_4502096-S
ACO2 GI_4501866-S CYP27A1 GI_13904863-S
SDHB GI_9257241-S MUT GI_4557766-S
SUCLG1 GI_11321580-S TXNRD2 GI_22035669-A
MDH2 GI_21735620-S NGFRAP1 GI_7657043-S
IDH2 GI_28178831-S POLG GI_4505936-S
PDHA1 GI_4505684-S
INS (Insulin) BCKDHB GI_34101266-A
SORBS1 GI_7661699-I SLC25A16 GI_31652216-S
PRKAR2B GI_4506064-S NFS1 GI_32307129-A
PDPK1 GI_4505694-S PDK3 GI_4885544-S
PRKCZ GI_10864649-S DECR1 GI_4503300-S
PIK3CB GI_5453893-S OAT GI_4557808-S
CRK GI_41327709-A CYC1 GI_21359866-S
FLOT2 GI_4758393-S PCCA GI_4557832-S
INPPL1 GI_4755141-S BCKDK GI_5031608-S
BCL2L1 GI_20336333-A
MAP00010_Glycolysis_Gluconeogenesis FIBP GI_38683847-S
DLAT GI_31711991-S HADHB GI_4504326-S
HK2 GI_40806188-S PPOX GI_45439340-S
DLD GI_5016092-S CPS1 GI_21361330-S
ALDH1B1 GI_25777729-S SDHA GI_4759079-S
PDHA1 GI_4505684-S ATP5B GI_32189393-S
ALDH3A2 GI_4557302-S DCI GI_4503266-S
ENO2 GI_16507966-S GCDH GI_4503942-I
BPGM GI_40353767-A TK2 GI_33636700-S
ENO3 GI_16554591-A IDH3A GI_28178835-S
PDHB GI_4505686-S PMPCB GI_4758733-S
ALDH3B1 GI_4502042-S SSBP1 GI_4507230-S
GPI GI_18201904-S PDHB GI_4505686-S
ALDH1A1 GI_25777722-S DGUOK GI_18426962-A
PFKM GI_39725712-S ACADS GI_4557232-S
GRCC9 GI_14249177-S MTIF2 GI_4505276-S
PFKL GI_21361069-S PDCD8 GI_22202627-I
LDHA GI_5031856-S MTERF GI_14790134-S
PGK1 GI_22095338-S NDUFA8 GI_33519464-S
HK1 GI_4504390-A CPT1B GI_23238255-A
ARG2 GI_10947110-S
MAP00561_Glycerolipid_metabolism IVD GI_6031167-S
PAFAH1B1 GI_6031206-S ATPIF1 GI_30260186-A
ALDH1B1 GI_25777729-S ACO2 GI_4501866-S
GK GI_42794761-S SDHB GI_9257241-S
SERPINB1 GI_20149554-S SUCLG1 GI_11321580-S
GLB1 GI_10834965-S FDX1 GI_36054077-S
ALDH3A2 GI_4557302-S AFG3L2 GI_5802969-S
DGAT1 GI_7382489-S GPX4 GI_4504106-S
CPT2 GI_4503022-S COX5A GI_17017986-S
DGKG GI_4503314-S CPT1A GI_4503020-S
GLA GI_4504008-S ATP5E GI_21327678-S
AKR1B1 GI_24497579-S ACAT1 GI_31563501-S
ALDH1A1 GI_25777722-S CYB5 GI_4503182-S
ALPP GI_13787194-S ACADVL GI_4557234-S
ALPI GI_13787191-S IDH2 GI_28178831-S
CPT1A GI_4503020-S CRAT GI_21618335-A
GRCC9 GI_14249177-S TUFM GI_34147629-S
BCKDHA GI_38372929-S
CKAP1 GI_4502848-S
HAX1 GI_13435355-S
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Up-regulation of cell cycle arrest and cell death pathways in response to knockdown of FAS Figure 3
Up-regulation of cell cycle arrest and cell death pathways in response to knockdown of FAS. The figure displays 
select pathways found to be up-regulated in response to FAS siRNA treatment compared to non-silencing control siRNA. Sig-
nificance was determined using a nominal p-value < 0.05 or FDR < 0.250. The expression levels of the genes significantly mod-
ified in the pathway are coded colorimetrically: red, high expression; blue, low expression. FAS siRNA treatments for each 
time point are ordered as follows (a and b indicate different biological replicates): FAS #1a, FAS #1b, FAS #2a, FAS #2b, FAS 
#3a, FAS #3b, FAS #4a, FAS #4b. For a complete list of all pathways up-regulated by knockdown of FAS, see Additional File 7.
Gene Symbol Gene ID FAS knockdown signature Gene Symbol Gene ID FAS knockdown signature
DNA damage signaling CR Death
RAD1 GI_19718798-A BAG4 GI_14574569-S
MRE11A GI_24234691-I TP53BP2 GI_4885642-S
TNFRSF10B GI_22547115-I CASP4 GI_15451908-A
CDC6 GI_16357469-S TRAF3 GI_22027615-A
ERCC1 GI_42544168-I CASP2 GI_39995062-A
BIRC2 GI_41349435-S BCL2A1 GI_14574570-S
CDC25B GI_11641410-A BNIP1 GI_7524347-A
RAD9A GI_19924112-S FOSL2 GI_13375679-S
LRDD GI_22325361-A BAX GI_34335114-I
CHEK2 GI_22209008-A CASP8 GI_15718711-A
FEN1 GI_19718776-S TRAF2 GI_22027613-A
RPL13A GI_14591905-S BAK1 GI_33457353-S
MLH1 GI_28559089-S STK17B GI_31543661-S
APEX1 GI_18375500-I BNIP2 GI_4757855-S
BAX GI_34335114-I CASP7 GI_15718701-A
TREX1 GI_18375534-A EVI1 GI_29789001-S
RAD51 GI_19924132-I MYC GI_31543215-S
MSH6 GI_4504190-S APAF1 GI_32483362-A
CDC25A GI_42490757-S
BAK1 GI_33457353-S Tnfr1 pathway
BCL6 GI_21040323-A MAP2K4 GI_24497520-S
CDK4 GI_16936531-I MAP3K1 GI_37550278-S
SRPX GI_21314639-S LMNA GI_27436944-A
GADD45B GI_9945331-S RIPK1 GI_24475887-S
PPIA GI_45439310-I BAG4 GI_14574569-S
PURA GI_16753217-S CASP2 GI_39995062-A
PPM1D GI_29558519-S DFFB GI_4758149-S
UNG GI_19718750-A CASP8 GI_15718711-A
APAF1 GI_32483362-A TRAF2 GI_22027613-A
CDKN1A GI_17978496-A RB1 GI_4506434-S
WEE1 GI_19718775-S TNFRSF1A GI_23312372-S
PAK1 GI_42794768-S
Cell cycle arrest PAK2 GI_32483398-S
GAS1 GI_4503918-S LMNB1 GI_27436949-S
GAS7 GI_41406075-A
CDKN2B GI_17981693-A Tnfr2 pathway
GMNN GI_41393571-S MAP3K1 GI_37550278-S
CDKN2A GI_17738293-I RELA GI_11496238-S
PPP1R15A GI_9790902-S RIPK1 GI_24475887-S
MYC GI_31543215-S TRAF3 GI_22027615-A
CDKN1A GI_17978496-A NFKBIA GI_10092618-S
CHUK GI_19923133-S
p27 pathway TRAF2 GI_22027613-A
CUL1 GI_32307160-S TANK GI_19743568-I
UBE2M GI_37577133-S TNFAIP3 GI_26051241-S
E2F1 GI_12669910-S NFKB1 GI_34577121-S
RB1 GI_4506434-S
TFDP1 GI_34147667-S
CKS1B GI_4502856-S
SKP2 GI_16306593-A
CDK2 GI_16936527-I
Rb pathway
CDC25B GI_11641410-A
YWHAH GI_21464102-S
CDC25A GI_42490757-S
RB1 GI_4506434-S
CDK4 GI_16936531-I
CDK2 GI_16936527-I
WEE1 GI_19718775-S
12h 24h 36h 48h 12h 24h 36h 48h C CBMC Genomics 2007, 8:168 http://www.biomedcentral.com/1471-2164/8/168
Page 9 of 13
(page number not for citation purposes)
lism as demonstrated by down-regulation in lipid
metabolism, glycolysis, krebs-TCA cycle and oxidative
phosphorylation pathways. Second, we show that loss of
FAS is anti-tumorigenic by up-regulating cell cycle arrest
and death receptor mediated apoptosis pathways. Third,
the inhibition of FAS leads to changes in genes that regu-
late transcription and ubiquitin-dependent protein degra-
dation. Altogether, these findings provide novel insight
into the cellular processes affected by knockdown of FAS
in tumor cells.
A vital assumption in siRNA-mediated gene silencing is
that knockdown of the target gene is exclusive, and with-
out off-target consequences. Yet, increasing evidence has
suggested siRNA can induce off-target effects that are
unique to the individual siRNA duplex, but unrelated to
the identity of the target gene [29]. These siRNA duplex
specific off-target effects are thought to arise from unin-
tended sequence homology with the off-target transcript.
In this study, we addressed the concern of potential siRNA
off-target effects by examining gene expression signatures
in response to four siRNA duplexes targeting different
regions of the FAS gene and focused our analysis on the
common gene changes that were associated with knock-
down of the enzyme. This eliminated off-target effects and
enabled us to study gene changes specifically associated
with knockdown of FAS. Altogether, evidence supporting
the role of FAS inhibition in inducing the described
genomic effects is as follows: first, we showed that FAS
siRNA strongly abrogates the expression of the FAS gene,
reduces FAS protein levels and blocks the biosynthetic
activity of the enzyme, as indicated by reduced [14C]mal-
onyl-CoA incorporation into palmitate. Second, pathway
analysis demonstrated that fatty acid biosynthesis and
metabolism are among the most significant pathways
down-regulated in response to FAS siRNA. Third, up-regu-
lation of the p27 and Rb gene pathways is consistent with
our prior work showing knockdown of FAS elicits a G1/S
arrest through these pathways [9]. We also found
increased expression of the p21Cip1 gene which is up-regu-
lated at the protein level in response to knockdown of FAS
[14,30]. Like p27, p21Cip1 acts as a negative regulator of
the G1/S transition by inactivating the cyclin-dependent
kinases that function to phosphorylate Rb and promote S
phase entry [31].
Knockdown of FAS by siRNA or the small molecule inhib-
itor Orlistat induces apoptosis by activating caspase 8
(Knowles LM and Smith JW, unpublished observations).
This is consistent with the current observation that siRNA
targeting FAS up-regulates TNF-α and TRAIL death recep-
tor mediated apoptosis pathways. In addition to TRAIL,
cell death through FAS inhibition has also been linked to
up-regulation of BNIP3 and DAP Kinase 2 [17]. These two
proapoptotic genes were detected by microarray analysis
72 h after FAS inhibition, which explains why we did not
observe similar changes as our study was limited to 48 h.
A possible mechanism accounting for the ability of FAS
inhibition to induce these apoptotic effects is the accumu-
lation of ceramide, which has been shown to induce these
death receptor pathways [32]. Ceramide accumulation is
the result of malonyl-CoA build-up following inhibition
of FAS [17]. Importantly, we have found that knockdown
of FAS up-regulates SGPL1. Ceramide generation and pro-
motion of cellular apoptosis have been observed in
response to increased expression of SGPL1 [18], suggest-
ing this enzyme may represent a leverage point by which
knockdown of FAS influences ceramide production.
In addition to changes in proliferation and survival,
knockdown of FAS also suppresses genes in the glycolysis,
krebs-TCA cycle and oxidative phosphorylation metabolic
pathways suggesting an overall reduction in cellular
energy metabolism. Consistent with the down-regulation
of oxidative phosphorylation gene expression, Chajès et
al. [33] report impaired mitochondrial function and gen-
eration of reactive oxygen species in response to FAS inhi-
bition. Targeted inactivation of ATP citrate lyase, a
lipogenic enzyme which functions immediately up-
stream FAS, has the opposite effect by stimulating mito-
chondrial function [34]. This is interesting as we have
found that knockdown of FAS, but not of ATP citrate
lyase, induces apoptosis (Knowles LM and Smith JW,
unpublished observations); raising the question of
whether the changes in cell survival and metabolism are
linked together. Indeed, growing evidence suggests TNF-α
may influence metabolism, as it can induce the down-reg-
ulation of genes involved in oxidative phosphorylation
[35], inhibition of electron transport chain activity [36]
and generation of reactive oxygen species [37]. Identifying
whether induction of apoptosis and reduced energy
metabolism are connected (via TNF-α or another molecu-
lar target) will be an important direction for future inves-
tigations, and may prove critical for understanding the
anti-tumorigenic benefits of a knockdown in tumor FAS.
The overall goal of our study was to define the regulatory
changes that take place following inhibition of tumor
FAS. To this end, we have identified a number of target
genes specifically modified by knockdown of FAS. Of par-
ticular interest among these are the dominant negative
HLH transcription repressors ID2 and ID3, which func-
tion to bind and inactivate the basic HLH family of tran-
scription factors [38], and therefore, are recognized for
their ability to block cell differentiation and promote pro-
liferation [39]. Like FAS, ID over-expression correlates
with tumor development in an array of cancers [40,41],
and knockdown of ID2/ID3 induces growth arrest and
apoptosis [39,42]. Our finding that knockdown of FAS
leads to the suppression of transcripts encoding ID2 andBMC Genomics 2007, 8:168 http://www.biomedcentral.com/1471-2164/8/168
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ID3  provides evidence of a link between FAS and ID
expression. This link is further supported by observations
that ID2/ID3 proteins can also suppress FAS gene expres-
sion by inactivating the basic HLH transcription factor
SREBP1 c that controls FAS expression [21]. Further char-
acterization of the molecular interplay between FAS and
ID is needed to more fully understand the role of these in
tumorigenesis.
Conclusion
In conclusion, this study provides a comprehensive data-
base of genomic changes that occur in response to knock-
down of FAS and confirms that FAS is central not only for
tumor cell metabolism but also for tumor cell signaling.
Further characterization of these signals on the protein
level will offer a more complete understanding of the cel-
lular targets and pathways affected by knockdown of FAS
and may lead to new therapeutic strategies for tumor pre-
vention and treatment.
Methods
Cell line and culture conditions
The MDA-MB-435 mammary tumor cell line was
obtained from Janet Price at the University of Texas South-
western. MDA-MB-435 cells were maintained in Mini-
mum Essential Medium Eagle (MEM) with Earl's Salts
(Mediatech, Inc., Herndon, VA, USA) supplemented with
10% fetal bovine serum (Irvine Scientific, Santa Ana, CA,
USA), 2 mM L-glutamine (Invitrogen Life Technologies,
Inc., Carlsbad, CA, USA), MEM vitamins (Invitrogen Life
Technologies, Inc.), nonessential amino acids (Medi-
atech, Inc.) and antibiotics (Omega Scientific, Inc., Tar-
zana, CA, USA). Cells were grown at 37°C under a
humidified, 5% CO2 atmosphere.
FAS gene silencing using siRNA
Four individual FAS siRNA sequences corresponding to 5'-
GAGCGUAUCUGUGAGAAACUU-3' (nucleotides 6241–
6259; FAS#1), 5'-GACGAGAGCACCUUUGAUGUU-3'
(nucleotides 1741–1749; FAS#2), 5'-UGACAUCGUCCA-
UUCGUUUUU-3' (nucleotides 1758–1776; FAS#3), 5'-
UGACAUCGUCCAUUCGUUUUU-3' (nucleotides
6236–6254; FAS#4) were designed and synthesized by
Dharmacon (Lafayette, CO, USA). MDA-MB-435 cells
were plated at 7.81 × 103 cells/cm2 in 10-cm2 plates and
grown for 24 h prior to transfection with 25 nM FAS#1,
FAS#2, FAS#3, FAS#4 or non-silencing control duplex #2
(D-001210-02) siRNA in Opti-MEM medium (Invitro-
gen) using Lipofectamine 2000 reagent (Invitrogen). After
5 h, transfection medium was replaced with normal cul-
ture medium and cells were grown for 12–48 h post-trans-
fection.
Real-time quantitative PCR
Total RNA was isolated from adherent cells using the Qia-
gen RNeasy kit (Qiagen, Inc, Valencia, CA, USA).
Genomic DNA contamination was removed using RNase-
Free DNase (Qiagen). RNA purity was assessed by A260/
A280 absorption and RNA integrity was verified by agarose
gel electrophoresis. cDNA was synthesized from 4 μg RNA
using the Superscript III First-Strand Synthesis System
(Invitrogen). Real-time quantitative PCR reactions were
performed using Power SYBR® Green PCR Master Mix
(Applied Biosystems, Foster City, CA, USA) on a Strata-
gene Mx3000p QPCR System (La Jolla, CA, USA). cDNA
was amplified using forward and reverse primers for FAS
(5'-AACTCCATGTTTGGTGTTTG-3' and 5'-CACATGCG-
GTTTAATTGTG-3') and normalized to the housekeeping
gene P0 (5'CAAGACTGGAGACAAAGTGG-3' and
5'AATCTGCAGACAGACACTGG-3'). The formation of a
single PCR product was verified using automated melting
curve analysis.
Western blot analysis
Adherent cell populations were lysed in 2× SDS sample
buffer, separated by SDS-PAGE and transferred to nitro-
cellulose as previously described [9]. Membranes were
probed for FAS and β-tubulin protein expressions using
anti-FAS (BD Transduction Laboratories, San Jose, CA,
USA) and anti-β-tubulin (Upstate Biotechnology, Lake
Placid, NY, USA) antibodies. Immunoreactivity was
detected using anti-mouse IgG conjugated peroxidase and
visualized by enhanced chemiluminescence.
FAS activity
FAS activity was determined by measuring the incorpora-
tion of [14C]malonyl-CoA into cellular fatty acids as previ-
ously described [9]. Briefly, MDA-MB-435 cells were lysed
in 20 mM Tris (pH 7.5), 1 mM dithiothreitol, and 1 mM
EDTA by sonication. Insoluble material was removed by
centrifugation (14,000 rpm) for 15 min at 4°C. The
resulting lysates (70 ug) were incubated in reaction buffer
containing 500 μM NADPH, 166.6 μM acetyl CoA, 100
mM KCl and 0.4 μCi [14C]malonyl-CoA (GE Healthcare,
Piscataway, NJ, USA) for 25 min at 37°C. Reactions were
chased with 25 nM cold malonyl-CoA for 15 min and ter-
minated by the addition of chloroform:methanol (1:1).
The chloroform extract was dried under N2 and extracted
with water-saturated butanol. The butanol extract was
evaporated under N2, and labeled fatty acids were
detected using a Beckman model LS 5000CE Scinillation
Counter (Beckman Coulter, Inc., Fullerton, CA, USA).
BeadArray gene expression
MDA-MB-435 cells were transfected with siRNA on two
separate occasions to generate independent measure-
ments for each treatment, and monitored for whole
genome expression at 12 h intervals over a 48 h timeBMC Genomics 2007, 8:168 http://www.biomedcentral.com/1471-2164/8/168
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period. Total RNA was isolated and examined for purity/
integrity as described above. Labeled cRNA was prepared
from 500 ng RNA using the Illumina® RNA Amplification
Kit from Ambion (Austin, TX, USA). The labeled cRNA
(1500 ng) was hybridized overnight at 55°C to the Sen-
trix® HumanRef-6 Expression BeadChip (>46,000 gene
transcripts; Illumina, San Diego, CA, USA) according to
the manufacturer's instructions. BeadChips were subse-
quently washed and developed with fluorolink streptavi-
din-Cy3 (GE Healthcare). BeadChips were scanned with
an Illumina BeadArray Reader and hybridization effi-
ciency was monitored using BeadStudio software (Illu-
mina) to measure internal controls built into the Illumina
system.
Expression data analysis
Expression data was filtered to identify genes expressed on
the BeadChip at >0.99 confidence (16,585 genes), and
normalized per chip using non-linear Normalize.quan-
tiles or VSN normalization to remove array to array varia-
bility (Bioconductor Project [43]). The efficiency of both
normalization methods were validated by measuring gene
to gene correlations across BeadChips according to the
methods of Ploner et al. [44] using R 2.0.1 software (R
Development Core Team, Vienna, Austria).
Differentially expressed genes that changed over time in
response to each of the four FAS siRNA duplex were iden-
tified using two independent methods. In the first
method, per chip normalized Normalize.quantiles data
was imported into the GeneSpring GX 7.3.1 software
package (Agilent Technologies, Palo Alto, CA, USA), and
per gene normalized to the appropriate biological control
for each time point. Genes that significantly changed over
time in response to each FAS siRNA duplex were com-
pared against control using a two-way ANOVA with a Ben-
jamini & Hochberg FDR of 0.05. In the second method,
VSN normalized data was imported into the Bioconductor
Timecourse package [43]. Genes regulated over time by
each FAS siRNA duplex in both biological replicates were
determined using mb. long() statistics, with an mb>0
used as criterion for the identification of significantly reg-
ulated genes. Genes identified as significant using these
two complementary approaches were combined, and
genes with a p-value ≤ 0.05 and with 1.2 fold changes in
both the biological replicates of each duplex at a given
time point, were maintained for expression analysis.
Genes identified as significantly modified by each of the 4
FAS siRNA duplexes were then overlapped using venn dia-
grams to identify a set of genes modified by 3 or more of
the siRNA treatments. Expression profiles of the core gene
list were averaged, and genes modified by 1.5 fold were
visually examined and ordered by hierarchical clustering
using the Pearson Correlation similarity measurement
(GeneSpring).
Gene set enrichment analysis
For pathway analysis, data from the 16,585 genes
expressed in MDA-MB-435 cells was exported from Gene-
Spring, filtered for duplicate symbols and analyzed using
GSEA software (Broad Institute) according to published
methods [26]. Briefly, data was overlapped on 522 gene
sets (s2.symbols.gmt) downloaded with the GSEA pack-
age and measured for the enrichment of genes at the top
or bottom of the gene list to determine their correlation
with the gene set's phenotype. The GSEA parameters used
included: metric for ranking genes, signal2noise; enrich-
ment statistic, weighted; permutation type, phenotype;
permutation number, 1000; and gene set size restrictions,
4 minimum, 500 maximum. Gene sets significantly mod-
ified by FAS siRNA treatment were identified using a nom-
inal p-value < 0.05 and a multiple hypothesis testing FDR
< 0.25. NES represents the enrichment of genes in the des-
ignated GSEA gene set, ranked according to the overrepre-
sentation of genes at the top or bottom of the list,
normalized to gene set size.
Abbreviations
FAS, fatty acid synthase; GSEA, Gene Set Enrichment Anal-
ysis; HLH, helix-loop-helix; siRNA, small interfering RNA;
SREBP, sterol regulatory element-binding protein; TRAIL,
TNF-related apoptosis-inducing ligand.
Authors' contributions
JS and LK conceived and designed the study. LK carried
out the siRNA transfections, validated target knockdown,
and prepared RNA for BeadArray expression profiling,
performed data analysis and drafted the manuscript. JS
supervised the coordination of the study and participated
in manuscript preparation. All authors read and approved
the final manuscript.
Additional material
Additional file 1
Genes significantly modified by FAS siRNA duplex #1 (≥1.2 or ≤0.83 
fold). The fold change values represent the average from 2 replicates of 
FAS siRNA duplex #1 compared to non-silencing control siRNA. Signifi-
cance was determined using a p-value of < 0.05, with a 1.2 fold change 
cutoff for both biological replicates at a given time point.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2164-8-168-S1.xls]
Additional file 2
Genes significantly modified by FAS siRNA duplex #2 (≥1.2 or ≤0.83 
fold). The fold change values represent the average from 2 replicates of 
FAS siRNA duplex #2 compared to non-silencing control siRNA. Signifi-
cance was determined using a p-value of < 0.05, with a 1.2 fold change 
cutoff for both biological replicates at a given time point.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2164-8-168-S2.xls]BMC Genomics 2007, 8:168 http://www.biomedcentral.com/1471-2164/8/168
Page 12 of 13
(page number not for citation purposes)
Acknowledgements
We wish to thank Kang Liu from the Burnham Institute for Medical 
Research Microarray Facility for BeadChip hybridizations and Roy Williams 
for help with gene analysis. This work was supported by Department of 
Defense Grant W81XWH-04-1-0515, and National Institutes of Heath 
Grant R01 CA108959 (to J.W.S.).
References
1. Wakil SJ: Fatty acid synthase, a proficient multifunctional
enzyme.  Biochemistry 1989, 28(11):4523-4530.
2. Kuhajda FP: Fatty-acid synthase and human cancer: new per-
spectives on its role in tumor biology.  Nutrition 2000,
16(3):202-208.
3. Piyathilake CJ, Frost AR, Manne U, Bell WC, Weiss H, Heimburger
DC, Grizzle WE: The expression of fatty acid synthase (FASE)
is an early event in the development and progression of squa-
mous cell carcinoma of the lung.  Hum Pathol 2000,
31(9):1068-1073.
4. Swinnen JV, Roskams T, Joniau S, Van Poppel H, Oyen R, Baert L,
Heyns W, Verhoeven G: Overexpression of fatty acid synthase
is an early and common event in the development of pros-
tate cancer.  Int J Cancer 2002, 98(1):19-22.
5. Alo PL, Visca P, Marci A, Mangoni A, Botti C, Di Tondo U: Expres-
sion of fatty acid synthase (FAS) as a predictor of recurrence
in stage I breast carcinoma patients.  Cancer 1996,
77(3):474-482.
6. Innocenzi D, Alo PL, Balzani A, Sebastiani V, Silipo V, La Torre G, Ric-
ciardi G, Bosman C, Calvieri S: Fatty acid synthase expression in
melanoma.  J Cutan Pathol 2003, 30(1):23-28.
7. Gansler TS, Hardman W 3rd, Hunt DA, Schaffel S, Hennigar RA:
Increased expression of fatty acid synthase (OA-519) in ovar-
ian neoplasms predicts shorter survival.  Hum Pathol 1997,
28(6):686-692.
8. Pizer ES, Chrest FJ, DiGiuseppe JA, Han WF: Pharmacological
inhibitors of mammalian fatty acid synthase suppress DNA
replication and induce apoptosis in tumor cell lines.  Cancer
Res 1998, 58(20):4611-4615.
9. Knowles LM, Axelrod F, Browne CD, Smith JW: A fatty acidsyn-
thase blockade induces tumor cell-cycle arrest by down-reg-
ulating Skp2.  J Biol Chem 2004, 279(29):30540-30545.
10. Kridel SJ, Axelrod F, Rozenkrantz N, Smith JW: Orlistat is a novel
inhibitor of fatty acid synthase with antitumor activity.  Can-
cer Res 2004, 64(6):2070-2075.
11. Pizer ES, Wood FD, Heine HS, Romantsev FE, Pasternack GR,
Kuhajda FP: Inhibition of fatty acid synthesis delays disease
progression in a xenograft model of ovarian cancer.  Cancer
Res 1996, 56(6):1189-1193.
12. Pizer ES, Thupari J, Han WF, Pinn ML, Chrest FJ, Frehywot GL,
Townsend CA, Kuhajda FP: Malonyl-coenzyme-A is a potential
mediator of cytotoxicity induced by fatty-acid synthase inhi-
bition in human breast cancer cells and xenografts.  Cancer Res
2000, 60(2):213-218.
13. De Schrijver E, Brusselmans K, Heyns W, Verhoeven G, Swinnen JV:
RNA interference-mediated silencing of the fatty acid syn-
thase gene attenuates growth and induces morphological
changes and apoptosis of LNCaP prostate cancer cells.  Can-
cer Res 2003, 63(13):3799-3804.
14. Menendez JA, Mehmi I, Atlas E, Colomer R, Lupu R: Novel signaling
molecules implicated in tumor-associated fatty acid syn-
thase-dependent breast cancer cell proliferation and sur-
vival: Role of exogenous dietary fatty acids, p53-p21WAF1/
CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB.  Int
J Oncol 2004, 24(3):591-608.
15. Wang HQ, Altomare DA, Skele KL, Poulikakos PI, Kuhajda FP, Di
Cristofano A, Testa JR: Positive feedback regulation between
AKT activation and fatty acid synthase expression in ovarian
carcinoma cells.  Oncogene 2005, 24(22):3574-3582.
16. Menendez JA, Vellon L, Mehmi I, Oza BP, Ropero S, Colomer R, Lupu
R: Inhibition of fatty acid synthase (FAS) suppresses HER2/
neu (erbB-2) oncogene overexpression in cancer cells.  Proc
Natl Acad Sci USA 2004, 101(29):10715-10720.
17. Bandyopadhyay S, Zhan R, Wang Y, Pai SK, Hirota S, Hosobe S,
Takano Y, Saito K, Furuta E, Iiizumi M, et al.: Mechanism of apop-
tosis induced by the inhibition of fatty acid synthase in breast
cancer cells.  Cancer Res 2006, 66(11):5934-5940.
18. Reiss U, Oskouian B, Zhou J, Gupta V, Sooriyakumaran P, Kelly S,
Wang E, Merrill AH Jr, Saba JD: Sphingosine-phosphate lyase
enhances stress-induced ceramide generation and apoptosis.
J Biol Chem 2004, 279(2):1281-1290.
19. Yang T, Espenshade PJ, Wright ME, Yabe D, Gong Y, Aebersold R,
Goldstein JL, Brown MS: Crucial step in cholesterol homeosta-
sis: sterols promote binding of SCAP to INSIG-1, a mem-
brane protein that facilitates retention of SREBPs in ER.  Cell
2002, 110(4):489-500.
20. Nogalska A, Sucajtys-Szulc E, Swierczynski J: Leptin decreases lipo-
genic enzyme gene expression through modification of
SREBP-1c gene expression in white adipose tissue of aging
rats.  Metabolism 2005, 54(8):1041-1047.
Additional file 3
Genes significantly modified by FAS siRNA duplex #3 (≥1.2 or ≤0.83 
fold). The fold change values represent the average from 2 replicates of 
FAS siRNA duplex #3 compared to non-silencing control siRNA. Signifi-
cance was determined using a p-value of < 0.05, with a 1.2 fold change 
cutoff for both biological replicates at a given time point.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2164-8-168-S3.xls]
Additional file 4
Genes significantly modified by FAS siRNA duplex #4 (≥1.2 or ≤0.83 
fold). The fold change values represent the average from 2 replicates of 
FAS siRNA duplex #4 compared to non-silencing control siRNA. Signifi-
cance was determined using a p-value of < 0.05, with a 1.2 fold change 
cutoff for both biological replicates at a given time point.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2164-8-168-S4.xls]
Additional file 5
FAS knockdown signature of 279 genes modified by 1.5 fold. The table 
displays genes modified by 1.5 fold compared to non-silencing control 
siRNA. The fold change values represent the average from at least 3 of the 
FAS siRNA duplexes.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2164-8-168-S5.xls]
Additional file 6
GSEA pathways down-regulated in response to knockdown of FAS. 
The table displays all pathways found to be down-regulated in response to 
FAS siRNA treatment compared to non-silencing control siRNA. Signifi-
cance was determined using a nominal p-value < 0.05 or FDR < 0.250.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2164-8-168-S6.xls]
Additional file 7
GSEA pathways up-regulated in response to knockdown of FAS. The 
table displays all pathways found to be up-regulated in response to FAS 
siRNA treatment compared to non-silencing control siRNA. Significance 
was determined using a nominal p-value < 0.05 or FDR < 0.250.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2164-8-168-S7.xls]Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Genomics 2007, 8:168 http://www.biomedcentral.com/1471-2164/8/168
Page 13 of 13
(page number not for citation purposes)
21. Moldes M, Boizard M, Liepvre XL, Feve B, Dugail I, Pairault J: Func-
tional antagonism between inhibitor of DNA binding (Id)
and adipocyte determination and differentiation factor 1/
sterol regulatory element-binding protein-1c (ADD1/
SREBP-1c) trans-factors for the regulation of fatty acid syn-
thase promoter in adipocytes.  Biochem J 1999, 344(Pt
3):873-880.
22. Matsumura ME, Lobe DR, McNamara CA: Contribution of the
helix-loop-helix factor Id2 to regulation of vascular smooth
muscle cell proliferation.  J Biol Chem 2002, 277(9):7293-7297.
23. Forrest ST, Taylor AM, Sarembock IJ, Perlegas D, McNamara CA:
Phosphorylation regulates Id3 function in vascular smooth
muscle cells.  Circ Res 2004, 95(6):557-559.
24. Nakayama KI, Nakayama K: Ubiquitin ligases: cell-cycle control
and cancer.  Nat Rev Cancer 2006, 6(5):369-381.
25. Thomson TM, Lozano JJ, Loukili N, Carrio R, Serras F, Cormand B,
Valeri M, Diaz VM, Abril J, Burset M, et al.: Fusion of the human
gene for the polyubiquitination coeffector UEV1 with Kua, a
newly identified gene.  Genome Res 2000, 10(11):1743-1756.
26. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gil-
lette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, et al.: Gene
set enrichment analysis: a knowledge-based approach for
interpreting genome-wide expression profiles.  Proc Natl Acad
Sci USA 2005, 102(43):15545-15550.
27. Sherr CJ, McCormick F: The RB and p53 pathways in cancer.
Cancer Cell 2002, 2(2):103-112.
28. Brusselmans K, De Schrijver E, Verhoeven G, Swinnen JV: RNA
interference-mediated silencing of the acetyl-CoA-carboxy-
lase-alpha gene induces growth inhibition and apoptosis of
prostate cancer cells.  Cancer Res 2005, 65(15):6719-6725.
29. Jackson AL, Bartz SR, Schelter J, Kobayashi SV, Burchard J, Mao M, Li
B, Cavet G, Linsley PS: Expression profiling reveals off-target
gene regulation by RNAi.  Nat Biotechnol 2003, 21(6):635-637.
30. Li JN, Gorospe M, Chrest FJ, Kumaravel TS, Evans MK, Han WF, Pizer
ES: Pharmacological inhibition of fatty acid synthase activity
produces both cytostatic and cytotoxic effects modulated by
p53.  Cancer Res 2001, 61(4):1493-1499.
31. Rank KB, Evans DB, Sharma SK: The N-terminal domains of cyc-
lin-dependent kinase inhibitory proteins block the phospho-
rylation of cdk2/Cyclin E by the CDK-activating kinase.
Biochem Biophys Res Commun 2000, 271(2):469-473.
32. Bollinger CR, Teichgraber V, Gulbins E: Ceramide-enriched
membrane domains.  Biochim Biophys Acta 2005, 1746(3):284-294.
33. Chajes V, Cambot M, Moreau K, Lenoir GM, Joulin V: Acetyl-CoA
carboxylase alpha is essential to breast cancer cell survival.
Cancer Res 2006, 66(10):5287-5294.
34. Hatzivassiliou G, Zhao F, Bauer DE, Andreadis C, Shaw AN, Dhanak
D, Hingorani SR, Tuveson DA, Thompson CB: ATP citrate lyase
inhibition can suppress tumor cell growth.  Cancer Cell 2005,
8(4):311-321.
35. Dahlman I, Forsgren M, Sjogren A, Nordstrom EA, Kaaman M, Nas-
lund E, Attersand A, Arner P: Downregulation of Electron Trans-
port Chain Genes in Visceral Adipose Tissue in Type 2
Diabetes Independent of Obesity and Possibly Involving
Tumor Necrosis Factor-{alpha}.  Diabetes 2006,
55(6):1792-1799.
36. Schulze-Osthoff K, Bakker AC, Vanhaesebroeck B, Beyaert R, Jacob
WA, Fiers W: Cytotoxic activity of tumor necrosis factor is
mediated by early damage of mitochondrial functions. Evi-
dence for the involvement of mitochondrial radical genera-
tion.  J Biol Chem 1992, 267(8):5317-5323.
37. Lo YY, Cruz TF: Involvement of reactive oxygen species in
cytokine and growth factor induction of c-fos expression in
chondrocytes.  J Biol Chem 1995, 270(20):11727-11730.
38. Benezra R, Davis RL, Lockshon D, Turner DL, Weintraub H: The
protein Id: a negative regulator of helix-loop-helix DNA
binding proteins.  Cell 1990, 61(1):49-59.
39. Barone MV, Pepperkok R, Peverali FA, Philipson L: Id proteins con-
trol growth induction in mammalian cells.  Proc Natl Acad Sci
USA 1994, 91(11):4985-4988.
40. Sikder HA, Devlin MK, Dunlap S, Ryu B, Alani RM: Id proteins in
cell growth and tumorigenesis.  Cancer Cell 2003, 3(6):525-530.
41. Coppe JP, Itahana Y, Moore DH, Bennington JL, Desprez PY: Id-1
and Id-2 proteins as molecular markers for human prostate
cancer progression.  Clin Cancer Res 2004, 10(6):2044-2051.
42. Asirvatham AJ, Schmidt MA, Chaudhary J: Non-redundant inhibi-
tor of differentiation (Id) gene expression and function in
human prostate epithelial cells.  Prostate 2006, 66(9):921-935.
43. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S,
Ellis B, Gautier L, Ge Y, Gentry J, et al.: Bioconductor: open soft-
ware development for computational biology and bioinfor-
matics.  Genome Biol 2004, 5(10):R80.
44. Ploner A, Miller LD, Hall P, Bergh J, Pawitan Y: Correlation test to
assess low-level processing of high-density oligonucleotide
microarray data.  BMC Bioinformatics 2005, 6:80.